Detalles de la búsqueda
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674077
2.
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
N Engl J Med
; 388(18): 1645-1656, 2023 May 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37133584
3.
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC).
PLoS Genet
; 19(1): e1010563, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36595552
4.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
5.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31166679
6.
Outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
Breast Cancer Res Treat
; 191(1): 137-145, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34609640
7.
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients.
Anticancer Drugs
; 33(1): e628-e634, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34407044
8.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
9.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
10.
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial.
Cancer
; 127(5): 700-708, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33290610
11.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33486783
12.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
N Engl J Med
; 379(20): 1926-1936, 2018 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30345905
13.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
N Engl J Med
; 379(2): 122-137, 2018 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29863451
14.
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Breast Cancer Res Treat
; 185(3): 697-707, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33159633
15.
Metaplastic breast cancer: Prognostic and therapeutic considerations.
J Surg Oncol
; 123(1): 61-70, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33047318
16.
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies.
Breast Cancer Res
; 22(1): 27, 2020 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164785
17.
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer.
Breast Cancer Res
; 22(1): 83, 2020 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758299
18.
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.
Br J Cancer
; 122(7): 1119, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31949268
19.
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Breast Cancer Res Treat
; 184(1): 23-35, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32783178
20.
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy.
Breast Cancer Res Treat
; 181(2): 347-359, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32274665